Literature DB >> 14574165

The effect of disease penetrance, family size, and age of onset on family history with application to setting eligibility criteria for genetic testing.

Alexandre Sibert1, David E Goldgar.   

Abstract

The concept of family history of disease has been used as a surrogate for genetic susceptibility in many epidemiological studies and has also been important as a criterion for selecting individuals for genetic testing. However, little is known about the precise interplay between the true genetic model (genotype-specific penetrances, age of onset distribution), life expectancy, and reproductive patterns in determining the level of family history. In order to address these questions, we performed a simulation study to address these relationships. Factors examined were the age-, sex-, and genotype-specific penetrance of the disease and the distribution of the number of offspring per family. When considering the average number of affected individuals among first-degree relatives of mutation positive probands, penetrance-related factors accounted for 64% of the variance in the average number of affected first-degree relatives, and 58% of the variance in the number of affected first- or second-degree relatives. In general, the average proportion of mutation-positive probands with at least one affected first-degree relative was low, especially for a sex-limited disease, ranging between 20% and 46%, depending on the lifetime penetrance in mutation carriers. Lack of family history among first-degree relatives of mutation positive probands is not necessarily unexpected even for loci conferring relatively high lifetime risk. In selecting probands for genetic testing, we found that under a wide variety of conditions, criteria based on the number of affected among first- and second-degree relatives were superior to those based on first-degree family history alone.

Mesh:

Year:  2003        PMID: 14574165     DOI: 10.1023/a:1023208707085

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  19 in total

1.  Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2.

Authors:  J L Hopper; M A Jenkins
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  The importance of a family history of breast cancer in predicting the presence of a BRCA mutation.

Authors:  W D Foulkes; J S Brunet; E Warner; P J Goodwin; W Meschino; S A Narod; P E Goss; G Glendon
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

3.  Variation in the interaction between familial and reproductive factors on the risk of breast cancer according to age, menopausal status, and degree of familiality.

Authors:  N Andrieu; T Prevost; T E Rohan; E Luporsi; M G Lê; M Gerber; D G Zaridze; Y Lifanova; R Renaud; H P Lee; S W Duffy
Journal:  Int J Epidemiol       Date:  2000-04       Impact factor: 7.196

4.  High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes.

Authors:  U Finckh; T Müller-Thomsen; U Mann; C Eggers; J Marksteiner; W Meins; G Binetti; A Alberici; C Hock; R M Nitsch; A Gal
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

5.  Why are the majority of hereditary cases of early-onset breast cancer sporadic? A simulation study.

Authors:  J Cui; J L Hopper
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-08       Impact factor: 4.254

6.  BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history.

Authors:  K E Malone; J R Daling; J D Thompson; C A O'Brien; L V Francisco; E A Ostrander
Journal:  JAMA       Date:  1998-03-25       Impact factor: 56.272

7.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.

Authors:  G Parmigiani; D Berry; O Aguilar
Journal:  Am J Hum Genet       Date:  1998-01       Impact factor: 11.025

Review 8.  Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease.

Authors: 
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

9.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

Authors:  D Shattuck-Eidens; A Oliphant; M McClure; C McBride; J Gupte; T Rubano; D Pruss; S V Tavtigian; D H Teng; N Adey; M Staebell; K Gumpper; R Lundstrom; M Hulick; M Kelly; J Holmen; B Lingenfelter; S Manley; F Fujimura; M Luce; B Ward; L Cannon-Albright; L Steele; K Offit; A Thomas
Journal:  JAMA       Date:  1997-10-15       Impact factor: 56.272

10.  Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.

Authors:  S V Hodgson; E Heap; J Cameron; D Ellis; C G Mathew; R A Eeles; E Solomon; C M Lewis
Journal:  J Med Genet       Date:  1999-05       Impact factor: 6.318

View more
  2 in total

1.  Contribution of the Defective BRCA1, BRCA2 and CHEK2 Genes to the Familial Aggregation of Breast Cancer: a Simulation Study Based on the Swedish Family-Cancer Database.

Authors:  Justo Lorenzo Bermejo; Alfonso García Pérez; Kari Hemminki
Journal:  Hered Cancer Clin Pract       Date:  2004-11-15       Impact factor: 2.857

2.  Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.

Authors:  Jingmei Li; Wei Xiong Wen; Martin Eklund; Anders Kvist; Mikael Eriksson; Helene Nordahl Christensen; Astrid Torstensson; Svetlana Bajalica-Lagercrantz; Alison M Dunning; Brennan Decker; Jamie Allen; Craig Luccarini; Karen Pooley; Jacques Simard; Leila Dorling; Douglas F Easton; Soo-Hwang Teo; Per Hall; Åke Borg; Henrik Grönberg; Kamila Czene
Journal:  Int J Cancer       Date:  2018-11-09       Impact factor: 7.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.